Castle Biosciences Says 699-Patient Decision Modeling Study Shows TissueCypher Would Raise Appropriate Barrett's Esophagus Management From 59.8% To 75.3%; Escalation In Non-Dysplastic Progressors From 30.4% To 56.9%